COVID-19: Prospective Challenges and Potential Vaccines

被引:0
|
作者
Nadeem, Muhammad Shahid [1 ]
Ali, Akbar [2 ]
Al-Ghamdi, Maryam A. [1 ]
Depfenhart, Markus [4 ,5 ]
Khan, Jalaluddin Azam [1 ]
Zamzami, Mazin A. [1 ]
Murtaza, Bibi Nazia [3 ]
Kazmi, Imran [1 ]
Rehman, Mujadid Ur [3 ]
机构
[1] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia
[2] Northern Border Univ, Coll Pharm, Rafha, Saudi Arabia
[3] Abbottabad Univ Sci & Technol AUST, Dept Microbiol, Abbottabad, Pakistan
[4] Venlo Univ BV, Fac Med, Venlo, Netherlands
[5] Med One Clin Hamburg, Hamburg, Germany
关键词
RESPIRATORY SYNDROME CORONAVIRUS; SARS-COV; SPIKE PROTEIN; INFLUENZA; EVOLUTION; EPIDEMIC; VIRUS; TRANSMISSION; OPTIMIZATION; IMMUNIZATION;
D O I
暂无
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Context . RNA viruses exhibit an extraordinary ability to evolve in a changing environment and to switch from animal hosts to humans. The ongoing COVID-19 pandemic, recognized as a respiratory disease, is an example of zoonotic transmission of the RNA virus known as SARS-CoV-2. The development and regulatory approval of a vaccine against SARS-CoV-2 pose multiple preventive and therapeutic challenges, especially during an ongoing pandemic. Objective . The review intended to examine the challenges and recent achievements in the development of vaccine candidates against COVID-19. Design . The research team performed a literature review, searching relevant and up to date information from the literature. The sources of data included Google Scholar, PubMed, NCBI, and Yahoo. The search terms used were COVID-19 challenges, SARS-CoV-2 prospective challenges, RNA viruses adoptability, host switching by RNA viruses, COVID-19 vaccines. Setting . The study took place at the digital libraries of contributing institutions. The data was combined, selected for further analysis and manuscript preparation at King Abdulaziz University. Results . RNA viruses with high rate of genome alterations and evolution have better chances to survive in the adverse environmental conditions by adopting the alternate host species. The recent epidemics such as SARS, MERS, and COVID-19 are examples of zoonotic transmission of RNA viruses from animal species to the humans. However, the mechanisms involved in the switching-on to new host species need further investigations to control the zoonotic transmissions in near future. As of April 2020, 115 candidate vaccines were being evaluated; 78 of them had been found to be active, and a few of them are in Phase I trials. In the development of different types of vaccine candidates against COVID19, multiple international pharmaceutical and biotechnology companies are involved. Conclusions . Emerging and re-emerging pathogenic RNA viruses pose a serious threat to human health. Little is known about the human-host adoptive mechanism for zoonotic transmission. Deep insights into the molecular mechanism responsible for the switching of animal or bird viruses to humans could provide target molecules or events to prevent such transmissions in the near future. Fast development and approval of efficacious and safe vaccines is key to the effort to provide preventive measures against COVID-19 and future viruses. However, the development and availability of a vaccine candidate is a time-consuming process and often can't be completed during an epidemic. Currently, several types of vaccines are under development, and most of them won't realistically be available in time for the present COVID-19 pandemic.
引用
收藏
页码:72 / 78
页数:7
相关论文
共 50 条
  • [21] The COVID-19 Vaccines: Recent Development, Challenges and Prospects
    Yan, Yuxin
    Pang, Yoongxin
    Lyu, Zhuoyi
    Wang, Ruiqi
    Wu, Xinyun
    You, Chong
    Zhao, Haitao
    Manickam, Sivakumar
    Lester, Edward
    Wu, Tao
    Pang, Cheng Heng
    VACCINES, 2021, 9 (04)
  • [22] Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer
    Kuderer, Nicole M.
    Hill, Joshua A.
    Carpenter, Paul A.
    Lyman, Gary H.
    CANCER INVESTIGATION, 2021, 39 (03) : 205 - 213
  • [23] New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals
    Chen, Jun
    Lu, Hongzhou
    BIOSCIENCE TRENDS, 2021, 15 (02) : 126 - 128
  • [24] Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development
    Daniela Calina
    Chandan Sarkar
    Andreea Letitia Arsene
    Bahare Salehi
    Anca Oana Docea
    Milon Mondal
    Muhammad Torequl Islam
    Alireza Zali
    Javad Sharifi-Rad
    Immunologic Research, 2020, 68 : 315 - 324
  • [25] Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development
    Calina, Daniela
    Sarkar, Chandan
    Arsene, Andreea Letitia
    Salehi, Bahare
    Docea, Anca Oana
    Mondal, Milon
    Islam, Muhammad Torequl
    Zali, Alireza
    Sharifi-Rad, Javad
    IMMUNOLOGIC RESEARCH, 2020, 68 (06) : 315 - 324
  • [26] Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
    Risma, Kimberly A.
    Edwards, Kathryn M.
    Hummell, Donna S.
    Little, Frederic F.
    Norton, Allison E.
    Stallings, Amy
    Wood, Robert A.
    Milner, Joshua D.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (06) : 2075 - +
  • [27] Development of potential COVID-19 vaccines continues to accelerate
    Kirby, Tony
    LANCET MICROBE, 2020, 1 (03): : E109 - E109
  • [28] COVID-19 pandemic: outbreak, potential vaccines and medications
    Bhat, Rauf
    Soliman, Sameh S. M.
    Ahmed, Magdy M. El-Sayed
    Husseiny, Mohamed, I
    RUSSIAN OPEN MEDICAL JOURNAL, 2021, 10 (04)
  • [29] The potential neurological effect of the COVID-19 vaccines: A review
    Lu, Lu
    Xiong, Weixi
    Mu, Jie
    Zhang, Qi
    Zhang, Hesheng
    Zou, Ling
    Li, Weimin
    He, Li
    Sander, Josemir W.
    Zhou, Dong
    ACTA NEUROLOGICA SCANDINAVICA, 2021, 144 (01): : 3 - 12
  • [30] Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
    Chavda, Vivek P.
    Vora, Lalitkumar K.
    Pandya, Anjali K.
    Patravale, Vandana B.
    DRUG DISCOVERY TODAY, 2021, 26 (11) : 2619 - 2636